Nutritional optimization of fecal microbiota transplantation in humans: a scoping review.|https://dx.doi.org/10.1080/19490976.2024.2446378
Factors for Treatment Failure After Fecal Microbiota Transplantation in Clostridioides difficile Infection.|https://dx.doi.org/10.3390/microorganisms12122539
Pilot study of Clostridioides difficile infection (CDI) in hospitals, Italy, September to December 2022.|https://dx.doi.org/10.2807/1560-7917.ES.2025.30.1.2400206
Clostridioides difficile infection and recurrence in cancer patients (CIRCA): a multicentre, international study.|https://dx.doi.org/10.1016/j.ijid.2025.107785
Synergistic and off-target effects of bacteriocins in a simplified human intestinal microbiome: implications for Clostridioides difficile infection control.|https://dx.doi.org/10.1080/19490976.2025.2451081
Management of Recurrent Clostridioides difficile Infection (rCDI): A Systematic Literature Review to Assess the Feasibility of Indirect Treatment Comparison (ITC).|https://dx.doi.org/10.1007/s40121-024-01105-y
The evolving landscape of live biotherapeutics in the treatment of Clostridioides difficile infection.|https://dx.doi.org/10.1007/s12664-024-01717-9
Current trends in antimicrobial use and the role of antimicrobial stewardship in palliative oncology: a narrative review.|https://dx.doi.org/10.1186/s12904-025-01649-x
Phenotypic analysis of various Clostridioides difficile ribotypes reveals consistency among core processes.|https://dx.doi.org/10.1101/2025.01.10.632434
Polysaccharide lyase PL3.3 possibly potentiatingÂ Clostridioides difficile clinical symptoms based on complete genome analysis of RT046/ST35 and RT012/ST54.|https://dx.doi.org/10.1007/s10123-025-00634-x
Cell Wall Protein 2 as a Vaccine Candidate Protects Mice Against Clostridioides difficile Infection.|https://dx.doi.org/10.3390/vaccines13010021
